Sugi Predict

Sugi Predict / Compounds / SCHEMBL558796

SCHEMBL558796

SCHEMBL558796

CC(C)(C)OC(=O)CCCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.35
▸ PRKCA P17252 6/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ HTR4 Q13639 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ PSMB8 P28062 1/20 0.31
▸ PSMB5 P28074 1/20 0.31
▸ TPSAB1 Q15661 1/20 0.31
▸ TPSD1 Q9BZJ3 1/20 0.31
▸ TPSG1 Q9NRR2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11920409 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL905426 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL11920413 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL557540 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL1676918 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL25434198 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL905423 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL1510015 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL15196458 0.95 EPHX2 (0.35) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL8740492 0.92 STING1 (0.34) EPHX2KMT2AALDH1A1PSMB8PSMB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122011156-A Weight-losing peptide with high activity and preparation method and application thereof 济南健丰化工有限公司 2026-05-12 — — CN disclosed
US-12552742-B2 Process for the preparation of Semaglutide side chain FRESENIUS KABI ONCOLOGY LTD (IN) 2026-02-17 — — US disclosed
US-20250250299-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2025-08-07 — — US disclosed
EP-4499667-A1 MACROCYCLIC IMMUNOMODULATORS Bristol-Myers Squibb Company (US) 2025-02-05 — — EP disclosed
CN-119013287-A Macrocyclic immunomodulators 百时美施贵宝公司 2024-11-22 — — CN disclosed
US-12097242-B2 Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides BRISTOL-MYERS SQUIBB COMPANY (US) 2024-09-24 — — US disclosed
US-12097241-B2 Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides BRISTOL-MYERS SQUIBB COMPANY (US) 2024-09-24 — — US disclosed
CN-118221561-A Method for preparing long-chain fatty acid derivative and application thereof 江苏万邦医药科技有限公司 2024-06-21 — — CN disclosed
US-11952434-B2 Immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-09 — — US disclosed
WO-2023192873-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-10-05 — — WO disclosed
EP-1846447-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2007-10-24 — — EP disclosed
EP-1846446-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2007-10-24 — — EP disclosed
US-20070129284-A1 Single-chain insulin NOVO NORDISK A/S (DK) 2007-06-07 — — US disclosed
EP-1692168-A1 SINGLE-CHAIN INSULIN NOVO NORDISK A/S (DK) 2006-08-23 — — EP disclosed
US-20060183668-A1 Antidiabetic agents; insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the alpha-amino group of the N-terminal amino acid residue of the B chain or to epsilon-amino group of a Lys residue present in the B chain of parent insulin NOVO NORDISK A/S (DK) 2006-08-17 — — US disclosed
WO-2006082204-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2006-08-10 — — WO disclosed
WO-2006082205-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2006-08-10 — — WO disclosed
EP-1660531-A2 NOVEL INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2006-05-31 — — EP disclosed
WO-2005054291-A1 SINGLE-CHAIN INSULIN NOVO NORDISK A/S (DK) 2005-06-16 — — WO disclosed
WO-2005012347-A2 NOVEL INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12097241-B2 Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides RXFP2, RXFP1, RXFP4 EPHX2 3868/4885SMN1; SMN2 809/4885KMT2A 3362/4885
US-11952434-B2 Immunomodulators CD74, ICOS, HAVCR2 EPHX2 2816/4885SMN1; SMN2 4268/4885KMT2A 3513/4885
US-20250250299-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 EPHX2 4718/4885SMN1; SMN2 4179/4885KMT2A 2293/4885
US-12097242-B2 Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides RXFP2, RXFP1, RXFP4 EPHX2 3339/4885SMN1; SMN2 587/4885KMT2A 1915/4885
US-20070129284-A1 Single-chain insulin IGF1R, IGFBP1, INSR EPHX2 4770/4885SMN1; SMN2 2115/4885KMT2A 2732/4885
US-12552742-B2 Process for the preparation of Semaglutide side chain GCG, FGF1, GLP1R EPHX2 272/4885SMN1; SMN2 2341/4885KMT2A 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.